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Summary
High-level expression of foreign proteins in chloroplasts of transplastomic plants provides
excellent opportunities for the development of oral vaccines against a range of debilitating or
fatal diseases. The HIV-1 capsid protein p24 and a fusion of p24 with the negative regulatory
protein Nef (p24-Nef) accumulate to 4% and 40% of the total soluble protein of leaves
of transplastomic tobacco (Nicotiana tabacum L.) plants. This study has investigated the
immunogenicity in mice of these two HIV-1 proteins, using cholera toxin B subunit as an
adjuvant. Subcutaneous immunization with purified chloroplast-derived p24 elicited a strong
antigen-specific serum IgG response, comparable to that produced by Escherichia coli-derived
p24. Oral administration of a partially purified preparation of chloroplast-derived p24-Nef
fusion protein, used as a booster after subcutaneous injection with either p24 or Nef, also
elicited strong antigen-specific serum IgG responses. Both IgG1 and IgG2a subtypes, associ-
ated with cell-mediated Th1 and humoral Th2 responses, respectively, were found in sera
after subcutaneous and oral administration. These results indicate that chloroplast-derived
HIV-1 p24-Nef is a promising candidate as a component of a subunit vaccine delivered by
oral boosting, after subcutaneous priming by injection of p24 and ⁄ or Nef.
Introduction
Acquired immunodeficiency syndrome (AIDS) is caused by
infection with the human immunodeficiency virus, HIV, which
apparently spread to the human population from non-human
African primates during the 20th century (Gallo, 2006). Around
33 million HIV infections were estimated worldwide in 2007,
and a large number of these infections are located in develop-
ing countries (WHO, 2009). A safe and effective vaccine to
reduce the transmission of HIV-1 infection or to prevent disease
progression is desperately needed, particularly in developing
countries (Essex, 1999). However, the development of a vaccine
for HIV has proved to be very difficult, partly because of the
complex nature of the virus (Crandall, 2001). HIV is highly
adaptable because of its high mutation rate and there are mul-
tiple strains belonging to a number of different clades (Spira
et al., 2003), so it is likely that a multi-component vaccine com-
prising several proteins or peptides will be necessary to invoke
broad and potent immunity. Subunit vaccines offer the advan-
tage of targeting specific epitopes that lie within conserved
areas of the virus. Two potential antigens, the 24-kDa capsid
protein p24 and the 31-kDa regulatory protein Nef, are the
focus of this study. The core protein p24 has 80% conservation
of identical amino acids across HIV-1 clades because of
structure ⁄ function constraints (Hanke and McMichael, 2000),
whereas Nef has a sequence identity of 84% and an average
similarity of 89% between five different subtypes (Geyer and
Peterlin, 2001).
Structural proteins, such as p24, are good candidates for vac-
cine components because of their high conservation (Novitsky
et al., 2001). In other virus infections, like hepatitis B and influ-
enza, immune responses directed at the viral core protein have
been shown to be protective (Russell and Liew, 1980; Iwarson
et al., 1985; Murray et al., 1987). Nef, on the other hand, is an
indispensable early post-infection regulatory protein (Hel et al.,
2002a). Studies in non-human primates have shown that vaccine-
induced cytotoxic T-lymphocyte responses against early proteins,
such as Nef, provide a degree of protection against pathogenic
virus challenges (Hel et al., 2002a). Both HIV p24 and Nef have
been part of several immunological trials and have shown the
capacity to induce strong, multi-epitopic CD4+ and CD8+ T-cell
responses (McMichael and Hanke, 2003; Girard et al., 2006).
Also, an immunogenicity study with a plant-derived p24-Ig anti-
gen-antibody fusion showed T-cell responses in mice (Obregon
et al., 2006). Cell-mediated immune responses against regulatory
proteins such as Nef may eliminate virus-infected cells at an early
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stage of viral replication, whereas cell-mediated immune
responses against the core protein p24 may eliminate infected
cells by specific cytolysis (Asakura et al., 1997). Both of these HIV
proteins are thus clear targets for a multi-component vaccine.
A vaccine containing both proteins may increase the probability
of achieving a long-lasting, efficient immune response.
HIV-1 p24 has previously been prepared in Escherichia coli
(Marczinovits et al., 1993; Hausdorf et al., 1994), yeast (Weber
et al., 1995), baculovirus (Mills and Jones, 1990) and in
tobacco, using transient expression (Zhang et al., 2000; Meyers
et al., 2008), stable nuclear transformation (Zhang et al., 2002;
Meyers et al., 2008) or chloroplast transformation (McCabe
et al., 2008; Zhou et al., 2008). HIV-1 Nef has been produced
in E. coli (Kohleisen et al., 1996), transgenic tobacco (Marusic
et al., 2007) and transplastomic tobacco (Zhou et al., 2008).
The p24 accumulation levels obtained in these systems vary
from 12 mg ⁄ L of rich medium in the E. coli system (Hausdorf
et al., 1994), 50 mg ⁄ L of culture in the baculovirus system
(Mills and Jones, 1990), 1 mg ⁄ kg fresh weight of leaves for
the transient protein expression system (Meyers et al., 2008),
35 mg ⁄ kg leaf soluble protein in transgenic tobacco (Zhang
et al., 2002) and 450 mg ⁄ kg fresh weight in transplastomic
plants (McCabe et al., 2008). The accumulation levels obtained
through chloroplast transformation are much higher than those
achieved in other systems (Oey et al., 2009; Bock and Warze-
cha, 2010; Ruhlman et al., 2010), and the antigens used in this
study, p24 and p24-Nef, accumulate to 4% and 40% of
total soluble leaf protein (Zhou et al., 2008). These levels are
likely to satisfy the demand for p24 and Nef as part of an HIV
vaccination programme, especially if large quantities are
required, as would probably be the case for an oral vaccine tar-
geted to developing countries.
Oral vaccines are likely to be in greater demand in developing
countries, because of ease of administration and no require-
ment for specialized personnel or an uninterrupted cool chain.
Also, they are better suited to produce mucosal responses,
essential for pathogens, such as HIV, that invade via these sites.
Antigens produced in plants may be enriched or partially puri-
fied prior to oral administration, or may simply be delivered as a
tissue homogenate without any purification, because oral vac-
cines do not require a high amount of purity (Walmsley and
Arntzen, 2003; Daniell et al., 2009). Vaccination with tissue ho-
mogenates may provide some protection, by bioencapsulation
of the antigen, against degradation or dilution in the digestive
system. Oral administration of chloroplast-derived antigens has
resulted in successful vaccination of mice against several pro-
teins, including tetanus toxin (Tregoning et al., 2005), a plague
fusion protein (Arlen et al., 2008), an E. coli enterotoxin fusion
protein (Rosales-Mendoza et al., 2009) and cholera toxin-
malaria antigen fusion proteins (Davoodi-Semiromi et al., 2010).
Here, the immunogenicity of tobacco chloroplast-derived p24
and a p24-Nef fusion protein was examined in mice following
subcutaneous injection of purified p24 and oral gavage of
enriched p24-Nef, partially purified to deplete potentially toxic
polyphenols and alkaloids, such as nicotine.
Results
Systemic immunogenicity of chloroplast-derived p24
Initially, the immunogenicity in mice of tobacco chloroplast-
derived p24 was compared to E. coli-derived p24, which is
known to be antigenic (Iroegbu et al., 2000). p24 was purified
to >95% homogeneity from transplastomic tobacco plants (cul-
tivar Maryland Mammoth) by a simple procedure involving
ammonium sulphate precipitation and cation-exchange chroma-
tography on Mono S-Sepharose (McCabe et al., 2008). The
material was assessed by SDS–PAGE and Coomassie-staining
and showed a single polypeptide of 24 kDa (Figure 1a). p24
was produced in E. coli as a His10-tagged protein and was puri-
fied from inclusion bodies on Ni-NTA agarose in the presence
of 8 M urea (Zhou et al., 2008). Following lipopolysaccharide
removal, the endotoxin-free preparation resolved as a predomi-
nantly 25-kDa band (because of the presence of the His10-tag),
with a small amount of higher molecular weight material
(Figure 1a). This figure also shows the Vibrio cholerae cholera
toxin B subunit (CTB) preparation which was used as an adju-
vant in all immunizations; the predominant band at 60 kDa is
the tightly linked pentameric form of 12 kDa B subunits. CTB
has been shown to enhance antigen presentation, promote iso-
type differentiation in B cells and stimulate T-cell proliferation
and lymphokine production, without generating unexpected
adverse responses (Holmgren et al., 1992).
Four groups of mice were used to compare the immunoge-
nicity of chloroplast-derived p24 and E. coli-derived p24. Two
groups were injected subcutaneously with 10 or 1 lg of chloro-
plast-derived p24, and the other two groups received either
10-lg E. coli-derived p24 or phosphate ⁄ citrate buffer pH 7.0,
as a negative control. Antibodies to p24 appeared after the first
immunization with the high dose of chloroplast-derived p24
and with E. coli-derived p24, and the antibody responses
increased after each subsequent injection (Figure 2a). Serial dilu-
tions of the sera gave similar end-point titres (1 : 6400) for
both chloroplast- and E. coli-derived p24 (Table 1). Antigen-
specific IgG was not detected in the preimmune sera (day )1),
nor in the sera from the buffer control group. The group that
received the low dose (1 lg) of chloroplast-p24 showed a very
(a) (b)
Figure 1 Antigens and adjuvant used for immunizations. Samples were
separated by electrophoresis in SDS 12% polyacrylamide gels. (a) Coo-
massie-stained gel loaded with 1-lg protein of each of the preparations
used for injection. From left to right, Vibrio cholerae cholera toxin B sub-
unit (60 kDa), Escherichia coli-derived HIV-1 p24 (25 kDa), E. coli-
derived HIV-1 Nef (27 kDa), tobacco chloroplast (Chl)-derived HIV-1
p24 (24 kDa) and 20 lL of a suspension (0.1 g freeze-dried powder in
5 mL water) of partially purified tobacco Chl-derived HIV-1 p24-Nef. (b)
Western blots of a gel loaded with 20 lL of a suspension of the partially
purified chloroplast-derived p24-Nef preparation and of a sample pre-
pared in the same way from wild-type (wt) tobacco leaves. The antibod-
ies used are indicated at the top (anti-p24 or anti-Nef). The position of
the marker proteins (low range; Bio-Rad) is shown on the left-hand side
of each part of the figure.
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low antibody response (titre of 1 : 800). This analysis clearly
demonstrated that chloroplast-derived p24 was immunogenic
when injected subcutaneously and did not differ substantially
from E. coli-derived p24.
The profile of antibody isotype responses, assessing the pres-
ence of p24-specific IgG1 and IgG2a subtypes in sera, was
determined by ELISA on pooled cull serum samples (Figure 2b).
The group that received the high dose (10 lg) of chloroplast-
derived p24 showed p24-specific IgG1 and IgG2a responses,
with titres of up to 1 : 6400 for IgG1 and 1 : 3200 for IgG2a
(Table 1). The group that received E. coli-derived p24 also pre-
sented both subtypes of IgG, with a slightly higher titre
(>1 : 12800) of IgG1 than achieved with chloroplast-derived
p24 and similar titres (1 : 3200) for IgG2a (Figure 2b). This
systemic IgG subtype analysis indicates the involvement of both
cell-mediated immune responses, via Th1 helper cells and
IgG2a, and humoral immune responses, via Th2 helper cells and
IgG1.
Oral immunogenicity of chloroplast-derived p24-Nef
The accumulation of the p24-Nef fusion protein in chloroplasts
of transplastomic tobacco was much higher (40% TSP) than
the accumulation of either p24 (4% TSP) or Nef individually
(Zhou et al., 2008), making it a favoured candidate for oral
administration. However, tobacco leaves contain large amounts
of phenolics and toxic alkaloids, such as nicotine, which might
compromise oral delivery. A partial purification protocol result-
ing in the removal of most of the polyphenolic compounds and
alkaloids was developed. Transplastomic tobacco leaves (cultivar
Petite Havana) were homogenized in four volumes of extraction
buffer containing 20% (w ⁄ v) Dowex-1 resin, which has been
shown to remove >95% of leaf polyphenols (Gray, 1978).
Some contaminating protein was removed from the leaf extract
by precipitation at pH 5.0 and by passage through an anion-
exchange Vivapure Q spin column, recovering the flow-through.
The protein content of the extract was decreased by 40%,
whereas the p24-Nef content, as assessed by p24-specific
ELISA, remained the same. Following dialysis against 10 mM
(NH4)2CO3, the extract was lyophilized, yielding 2.5 g of pow-
der from 100 g of leaves. SDS–PAGE of the lyophilized material
showed a prominent Coomassie-stained band at 55 kDa against
a background of a range of other polypeptides (Figure 1a).
Antibodies to p24 and to Nef both detected a predominant
55 kDa polypeptide, of the expected size for a p24-Nef fusion
protein, on Western blots (Figure 1b). Additional immunoreac-
tive bands of 20–25 kDa may represent cleaved monomeric
p24 or Nef polypeptides or degradation products.
The nicotine contents of the leaves and the lyophilized leaf
extract were assessed by HPLC following extraction with acidi-
fied methanol. Leaves contained 12.2 ± 2.3 nmol nicotine per
mg fresh weight (2 mg nicotine per g fresh weight), which is
comparable to published amounts for other cultivars (Djordjevic
and Doran, 2009). The partially purified leaf extract contained
the equivalent of 0.25 nmol nicotine per mg fresh leaf, repre-
senting a >95% reduction in nicotine content, and providing
material for oral administration by gavage that contained
168 lg nicotine per dose.
Five groups of mice were used to assess the oral immuno-
genicity of chloroplast-derived p24-Nef, and to compare the
response to that obtained by oral administration of p24 or Nef,
expressed in E. coli. Each of these groups received doses of
50 lg of antigen (p24-Nef, p24 or Nef), administered by oral
gavage. A negative control group received the equivalent
amount of wild-type tobacco leaf extract, processed in exactly
the same way as tobacco expressing the p24-Nef fusion pro-
tein, but not containing any immunoreactive p24 or Nef pro-
teins (Figure 1b). In addition, one further group of mice was
primed subcutaneously with both 10-lg E. coli-derived p24 and
10-lg E. coli-derived Nef, before being immunized orally with
50-lg chloroplast-derived p24-Nef. CTB (10 lg) was included as
an adjuvant in all immunizations. Serum samples were analysed
for the presence of p24- and Nef-specific IgG antibodies by
ELISA. The titres reached by each group at the different time
points are shown in Figure 3a (p24-specific responses) and in
Figure 3b (Nef-specific responses).
Only E. coli-derived p24 elicited a good p24-specific IgG
response among the groups receiving only orally administered
antigens, although three immunizations were required to reach
the maximum response. Administering three doses of 50 lg of
tobacco-derived p24-Nef, by gavage, did not prompt a serum
(a)
(b)
Figure 2 Analysis of antibody (IgG) response following subcutaneous
administration of chloroplast-derived (Chl) and Escherichia coli-derived
HIV-1 p24. Four groups of six female 5-week-old C57BL ⁄ 6J mice were
injected subcutaneously with 10 or 1 lg of chloroplast-derived p24,
10-lg E. coli-derived p24 or phosphate ⁄ citrate buffer pH 7.0, as a nega-
tive control. All injections included 10-lg cholera toxin B subunit as an
adjuvant. Mice were immunized on days 1, 17 and 38, before culling on
day 55. Blood samples were taken 1 day before each immunization, and
on day 55. Serum samples from each group of mice were pooled at
each time point, and serial twofold dilutions (shown on the right) were
analysed by p24-specific ELISA using wells coated with chloroplast-
derived p24 and horseradish peroxidase-linked sheep anti-mouse IgG to
detect the bound p24-specific antibodies. (a) p24-specific IgG antibody
titres of serum samples after the different immunization time points
(days are indicated on the x axis). (b) IgG subtype analysis showing
p24-specific IgG1 and IgG2a antibody titres of pre-immunization and
cull (day 55) serum samples of high-dose (10-lg p24) groups.
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response to either p24 or Nef. The reason for the lack of
response to p24-Nef is unknown. Neither E. coli-derived Nef
nor wild-type tobacco extract generated any antigen-specific
IgG response when administered orally. However, in the group
primed with E. coli p24 and E. coli Nef and boosted with
tobacco p24-Nef, specific anti-p24 and anti-Nef antibodies were
detected 13 days after priming and greatly increased after
boosting with the plant-derived material. The p24-specific
response increased approximately threefold after the first oral
boost and appeared to be maximal, as there was little further
change after the second and third gavages (Figure 3a). The
Nef-specific response was somewhat slower, requiring two
boosts of p24-Nef before reaching the maximum response
(Figure 3b). E. coli-derived Nef was a poor mucosal antigen
when delivered orally on its own, failing to generate any appre-
ciable IgG response. However, an anti-Nef IgG response was
elicited by priming with E. coli-derived Nef and boosting with
plant-derived p24-Nef, confirming the mucosal antigenicity of
the HIV chloroplast-derived fusion protein.
Analysis of the IgG subtype on the pooled cull serum sam-
ples, by ELISA, showed p24-specific IgG1 and IgG2a responses
in the mice that received E. coli-derived p24 orally (Figure 3c).
However, much higher p24-specific IgG1 and IgG2a responses
were obtained in the group primed subcutaneously with E. coli-
derived p24 and Nef and boosted orally with plant-derived p24-
Nef (Figure 3c). These mice also showed a strong Nef-specific
IgG1 response, but a weaker Nef-specific IgG2a response, indi-
cating a lower Th1-mediated cellular response to Nef. No anti-
gen-specific IgG subclasses could be detected in sera of mice
receiving oral doses of E. coli-derived Nef or the leaf extract
from wild-type tobacco. This IgG subtype analysis indicated that
oral boosting with partially purified p24-Nef fusion protein is
able to elicit strong cell-mediated and humoral immune
responses against p24, with weaker responses against Nef.
Prime-boost strategy with p24, Nef and p24-Nef
In view of the strong immune responses obtained in mice
primed subcutaneously with E. coli-derived p24 and Nef and
boosted orally with chloroplast-derived p24-Nef, a follow-up
study was designed to examine further the potential of the
prime-boost strategy, comparing priming with either p24 or
Nef, and boosting with p24-Nef, p24 or Nef. Purified E. coli-
derived p24 and Nef and partially purified tobacco p24-Nef
were used as in the previous experiment. Six groups of mice
were used: three groups were primed subcutaneously with
10-lg E. coli-derived p24 and three groups were primed
subcutaneously with 10-lg E. coli-derived Nef. The three p24-
primed groups were subsequently boosted, by gavage, with
either 50-lg partially purified tobacco-derived p24-Nef, 50-lg
E. coli-derived p24 or phosphate-buffered saline (PBS) (used as
a control), whereas the three Nef-primed groups received either
50-lg partially purified tobacco-derived p24-Nef, 50-lg E. coli-
derived Nef or PBS, by gavage. CTB (10 lg) was included as an
adjuvant in all immunizations.
Analysis of the serum samples by ELISA for p24- and Nef-
specific IgG antibodies clearly showed that boosting with
tobacco-derived p24-Nef elicited the greatest immune responses
(Figure 4). The plant-derived p24-Nef fusion protein was a more
potent booster than E. coli-derived p24 in eliciting p24-specific
antibodies (Figure 4a) and a more potent booster than E. coli-
derived Nef in eliciting Nef-specific antibodies (Figure 4b). Only
one boost with p24-Nef was necessary to maximize the anti-
p24 IgG response, with subsequent boosts maintaining the
response, whereas with p24 as a booster, the response
increased with each boost, without ever reaching the anti-p24
IgG titres (1 : 12800) obtained with tobacco-derived p24-Nef
(Figure 4a). In fact, the responses obtained by oral boosting
with p24 were not much higher than those obtained by solely
priming with p24. Oral boosting with E. coli-derived Nef was
even less effective, with no increased response over that
obtained solely by subcutaneous priming with Nef (Figure 4b).
Boosting with tobacco-derived p24-Nef, after priming with Nef,
elicited a strong Nef-specific response that stabilized after the
second oral boost (Figure 4b).
Attempts to detect a mucosal immune response by measure-
ment of p24- and Nef-specific IgA in faecal samples and vaginal
Table 1 Endpoint titres of ELISA assays for antigen-specific IgGs in cull serum samples. The endpoint titre is defined as the reciprocal of the
highest serum dilution that gave a reading above that of the pre-immunization serum or of the negative control group. Only dilutions up to
1 : 800 were assayed for IgG1 and IgG2a subtypes in the serum samples from the prime-boost experiment in Figure 4
Immunization IgG titre IgG1 titre IgG2a titre IgG1 : IgG2a ratio
Escherichia coli p24 (10 lg) SC 6400 12 800 3200 4.0
Chl p24 (1 lg) SC 800 800 400 2.0
Chl p24 (10 lg) SC 6400 6400 3200 2.0
Chl p24-Nef (50 lg) Oral – – – –
E. coli p24 (50 lg) Oral 12 800 >800 200 >4
E. coli Nef (50 lg) Oral – – – –
E. coli p24 & Nef (10 lg) SC + Chl p24-Nef (50 lg) Oral 12 800 (p24)
6400 (Nef)
>800
>800
>800
400
1 (p24)
>2 (Nef)
E. coli p24 (10 lg) SC + Chl p24-Nef (50 lg) Oral >12 800 >800 >800 2
E. coli p24 (10 lg) SC 3200 >800 >800 2
E. coli p24 (10 lg) SC + E. coli p24 (50 lg) Oral 6400 >800 >800 1
E. coli Nef (10 lg) SC + Chl p24-Nef (50 lg) Oral 3200 >800 800 2
E. coli Nef (10 lg) SC 400 200 100 2.0
E. coli Nef (10 lg) SC + E. coli Nef (50 lg) Oral 800 400 100 4.0
SC, subcutaneous.
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washes by ELISA were unsuccessful. Faecal samples produced a
very high background in the ELISAs and vaginal washes gave
very low readings, possibly because of excessive dilution of the
samples.
Discussion
The oral administration of chloroplast-derived HIV-1 p24-Nef
has been shown to be an effective means of generating a
immune response, targeting both p24 and Nef proteins, follow-
ing subcutaneous priming with the individual p24 and Nef anti-
gens. The immune response generated was associated with
both Th1 and Th2 helper cells, as indicated by the presence of
antigen-specific IgG1 and IgG2a subtypes, suggesting the stimu-
lation of a mixed cell-mediated and humoral response. Such a
response has been correlated with a higher degree of protec-
tion against intracellular pathogens such as HIV (Johnston and
Fauci, 2007). Prime-boost strategies have been widely used
against HIV in mice and macaques trials (Haglund et al., 2002;
Takeda et al., 2003) and generate strong, broad immune
responses that are greater than can be attained by single
vaccine strategies. Prime-boost vaccination strategies in other
(a)
(b)
(c)
Figure 3 Analysis of antibody (IgG) response following oral administra-
tion of tobacco chloroplast-derived p24-Nef. Three groups of six female
BALB ⁄ C mice received 50 lg of antigen (p24-Nef, p24 or Nef) adminis-
tered by oral gavage, one group was primed subcutaneously with 10-lg
Escherichia coli-derived p24 and 10-lg E. coli-derived Nef, before oral
gavage with 50-lg chloroplast-derived p24-Nef, and a negative control
group received wild-type tobacco leaf extract. All antigens were admin-
istered with 10-lg cholera toxin B subunit, as an adjuvant. E. coli-
derived p24 and Nef were injected subcutaneously on day 1, followed
by oral administration of antigens to all groups by gavage on days 14,
28 and 43. Blood samples were collected 1 day prior to each immuniza-
tion and on day 52, when the mice were culled. Serum samples from
each group of mice were pooled at each time point, and serial twofold
dilutions (shown on the right) were analysed for the presence of p24-
and Nef-specific IgG antibodies by ELISA. (a) p24-specific IgG antibody
titres of serum samples, using wells coated with E. coli-derived p24. (b)
Nef-specific IgG antibody titres of serum samples, using wells coated
with E. coli-derived Nef. (c) IgG subtype analysis showing p24-specific
and Nef-specific IgG1 and IgG2a antibody titres of pre-immunization
and cull (day 52) serum samples.
(a)
(b)
Figure 4 Analysis of antibody (IgG) response following oral administra-
tion of tobacco chloroplast-derived p24-Nef, as a booster after subcuta-
neous administration of Escherichia coli-derived p24 and Nef. Three
groups of five BALB ⁄ C female mice were primed subcutaneously with
10-lg E. coli-derived p24 and three groups were primed subcutaneously
with 10-lg E. coli-derived Nef. The three p24-primed groups were sub-
sequently boosted, by gavage, with either 50-lg partially purified
tobacco-derived p24-Nef, 50-lg E. coli-derived p24 or phosphate-
buffered saline (PBS) (as a control), whereas the three Nef-primed
groups received either 50-lg partially purified tobacco-derived p24-Nef,
50-lg E. coli-derived Nef or PBS, by gavage. All preparations were given
with 10-lg cholera toxin B subunit as an adjuvant. Antigens were
administered on day 1 (priming), 24, 38 and 52 (boosting), before
culling on day 67, and blood samples were collected 1 day before each
of the boosts. Serum samples from each group of mice were pooled at
each time point, and serial twofold dilutions (shown on the right) were
analysed by ELISA for p24- and Nef-specific IgG antibodies. (a)
p24-specific IgG antibody titres of serum samples, using wells coated
with E. coli-derived p24. (b) Nef-specific IgG antibody titres of serum
samples, using wells coated with E. coli-derived Nef.
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studies have shown great potential for stimulation of long-term
immune responses (Haglund et al., 2002; Hel et al., 2002b;
Takeda et al., 2003; Pal et al., 2005). A subcutaneous prime-
oral boost strategy has also been successful with other chloro-
plast-derived antigens, including a plague F1-V fusion protein
and CTB-malaria antigen fusions (Arlen et al., 2008; Davoodi-
Semiromi et al., 2010). Although E. coli-derived p24 was used
for subcutaneous priming in the experiments shown in Figures 3
and 4, tobacco chloroplast-derived p24 should be just as effec-
tive. The immunogenicity of purified chloroplast-derived p24
was comparable with purified E. coli-derived p24 when adminis-
tered subcutaneously (Figure 2).
In our study, a greater immune response was obtained by
oral delivery of p24-Nef as a booster than by boosting with
E. coli-derived p24 or Nef antigens. There are several possible
explanations for this observation. Firstly, the conformation of
p24 and Nef in the p24-Nef fusion protein may be different to
the individual proteins and this may enhance their antigenicity
in mice through increased exposure or presentation of specific
epitopes. Secondly, there may be additional adjuvants in the
plant material, which may enhance the immune response in
mice. Although CTB was included as an adjuvant in all immuni-
zations, leaves contain relatively large amounts of various mem-
bers of the Hsp70 and Hsp60 heat-shock protein families (Ellis,
1990; Marshall et al., 1990), which are known to act as adju-
vants in other systems (Suzue and Young, 1996; Wang et al.,
2002). The Hsp60 chaperonin Cpn60 is the second most abun-
dant protein in chloroplasts (Ellis, 1990) and is homologous to
bacterial GroEL ⁄Cpn60 proteins (Hemmingsen et al., 1988) that
stimulate cytokine release and have adjuvant activity (Friedland
et al., 1993; Carnelli Gebara et al., 2007). In addition, the
abundant ER-located Hsp70 BiP homologue from plants has
been shown to act as an adjuvant by activating dendritic cells
and stimulating humoral immune responses in mice (McGowan,
E. G., Gonzalez-Rabade, N., Nuttall, J., van Dolleweerd, C.,
Frigerio, L. and Ma, J. K-C., unpublished). Thirdly, there may be
additional components in the plant extract that enhance uptake
of the p24-Nef protein across the gut mucosal surface via M
cells (Man et al., 2004).
Although transplastomic tobacco plants accumulate the p24-
Nef fusion protein to 40% of total soluble protein in leaves
(Zhou et al., 2008), the removal of potentially toxic leaf com-
ponents, such as polyphenols and alkaloids, was perceived to
be necessary before oral administration. The LD50 values for
oral administration of nicotine are reported to be 3.34, 8.55
and 65 mg ⁄ kg for the free base, the hemisulphate and the
ditartrate, respectively (Registry of Toxic Effects of Chemical
Substances 1985–1986). For a 20-g mouse, this equates to
0.07, 0.17 and 1.3 mg (for the free base, the hemisulphate
and the ditartrate). The measured amount of nicotine in the
transplastomic tobacco leaves used in this study was
12.2 mmol ⁄ g fresh weight, which corresponds to 2 mg ⁄ g fresh
weight or 1.7% dry weight. The partial purification procedure
reduced this by >95%, so that the amount of nicotine admin-
istered per dose was 0.17 mg. This value is similar to the LD50
for nicotine hemisulphate, but no adverse effects on the mice
were observed in any of the experiments. Unprocessed tobacco
leaf homogenates have been administered orally to mice in
most previous studies of oral vaccination with chloroplast-
expressed antigens without any reports of toxic effects on the
mice (Tregoning et al., 2005; Ruhlman et al., 2007; Arlen
et al., 2008; Rosales-Mendoza et al., 2009; Davoodi-Semiromi
et al., 2010). Guetard et al. (2008) have reported mice con-
suming 0.1 g per day of lyophilized tobacco leaves (corre-
sponding to 1 g fresh weight) for at least 1 month without
showing any evident health problems. This indicates that the
nicotine in leaves and leaf extracts is not in a highly toxic form
and is probably in a salt form with a much higher LD50. Most
of these studies have used the tobacco cultivar Petite Havana,
which contains about 1.7% nicotine on a dry weight basis,
although Arlen et al. (2008) used the low-nicotine tobacco line
LAMD 609, which contains only 0.06% nicotine (Aycock and
Mulchi, 1998).
It has previously been suggested that about 100-fold more
antigen would need to be administered orally to induce a pro-
tective immune response compared to the amount delivered
by injection (Streatfield and Howard, 2003). However, only
fivefold higher doses proved to be sufficient to generate an
immune response when the plant-derived p24-Nef was used
as an oral booster in the prime-boost strategy (Figures 3 and
4). Priming subcutaneously with p24 or Nef and boosting
orally with p24-Nef was able to provoke a recall response,
maintaining or increasing the antigen-specific IgG titres with
each boost. Given the potent cross-clade humoral and T-cell
immunity required for protection against HIV (Webster et al.,
2005), plant-made HIV vaccines could find their niche as boos-
ter immunizations in prime-boost vaccine schedules. Oral
administration is a very practical way to deliver vaccines, espe-
cially in developing countries, and does not require syringes,
needles or trained personnel for administration. These features
would favour the use of plant-derived oral vaccines for large-
scale immunization programs, particularly in developing coun-
tries with limited resources. Production of HIV antigens in
plants should be a relatively inexpensive means of obtaining
large quantities of protein required for widespread, multiple-
dose vaccination in developing countries. Optimal doses of
plant-derived antigens for stimulation of protective levels of
antibody production lie in the range of 10–50 lg for primary
immunization and 50–150 lg for boosting regimes (Kong
et al., 2001). With the transplastomic tobacco plants used in
this study, grown under greenhouse conditions, 1 g p24 and
6 g p24-Nef would be produced per plant (McCabe et al.,
2008; Zhou et al., 2008). A hectare of transplastomic plants
grown under similar conditions would be able to generate
enough priming and boosting doses to immunize millions of
people.
There are many options for processing plant tissues to allow
for delivery of a well-characterized product. A purification strat-
egy for chloroplast-derived p24 was shown to produce an anti-
gen at 95% homogeneity (McCabe et al., 2008), suitable for
subcutaneous administration. Enrichment techniques, such as
acid precipitation and ion-exchange chromatography followed
by freeze-drying, increased the concentration of chloroplast-
derived p24-Nef and removed >95% of potentially toxic
polyphenols and alkaloids, generating material suitable for oral
administration. However, this processing of the leaf extracts
removes one of the potential advantages of leaf material for
oral delivery, that of bioencapsulation, which decreases the
probability of degradation and dilution of the antigens within
the digestive system. An alternative strategy avoiding processing
leaf extracts to remove toxic components might include the
production of transplastomic lines of palatable food materials,
such as lettuce or tomato. Lettuce is probably the favoured crop
for production of leaf-derived vaccine components (Ruhlman
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et al., 2007, 2010; Davoodi-Semiromi et al., 2010) using chloro-
plast transformation (Lilivelt et al., 2005; Kanamoto et al.,
2006). The accumulation of foreign proteins up to 25% of total
leaf protein has been obtained with lettuce (Ruhlman et al.,
2010). Although p24-Nef accumulated at up to 40% of the
total soluble protein of tomato leaves, lower amounts (up to
2.5% TSP) were observed in green tomato fruit (Zhou et al.,
2008).
Experimental procedures
Expression, extraction and purification of E. coli-
derived p24 and Nef
p24 with an N-terminal His10 tag was extracted and purified
from a 2-L culture of E. coli BL21 (Studier and Moffatt, 1986)
transformed with pET16bp24 (Zhou et al., 2008), incubated for
6 h at 37 C following induction with 1 mM IPTG. Inclusion
bodies were solubilized in 8 M urea and His-tagged p24 purified
on Ni-NTA agarose (Zhou et al., 2008). Urea was removed by
two rounds of dialysis against 5 L of PBS. Lipopolysaccharide
was removed by incubation for 1 h at room temperature with
polymyxin B immobilized on 4% cross-linked agarose beads
equilibrated with 0.2 M NaH2PO4 ⁄ 0.3 M citrate buffer pH 7.0.
The Limulus Amebocyte Lysate (LAL) QCL 1000 kit (Cambrex,
Charles City, IA) was used to confirm the absence of endotoxins
in the p24 preparation, following the manufacturer’s instruc-
tions. Purified E. coli-derived Nef [EVA650, Strain III], produced
by Prof. Volker Erfle (University of Munich, Germany) and Prof.
Mauro Magnani (University of Urbino, Italy), was supplied by
the National Institute for Biological Standards and Control
(NIBSC, Potters Bar, Hertfordshire, UK).
Purification of chloroplast-derived p24
p24 was purified from 50- to 75-g batches of leaves of
12-week-old transplastomic tobacco (cultivar Maryland Mam-
moth) plants containing the pZF5 vector, by ammonium
sulphate precipitation and cation-exchange chromatography on
Mono S-Sepharose spin columns, as described by McCabe et al.
(2008). The concentration of the purified preparation of chloro-
plast-derived p24 was determined from its absorbance at
280 nm, using a value of 1.204 for a solution containing 1-mg
p24 ⁄mL (Zhou et al., 2008).
Partial purification of chloroplast-derived p24-Nef
Chloroplast-derived p24-Nef fusion protein was extracted from
100 g of leaves of tobacco (N. tabacum L. cv. Petite Havana)
containing the construct pZF7lox (Zhou et al., 2008) by homog-
enization in a Waring blender with 400 mL of extraction buffer
[37.5 mM Tris–HCl pH 7.5, 50 mM NaCl, 15 mM EDTA, 75 mM
trisodium citrate, 0.2% (w ⁄ v) sodium thiosulphate, with 40-lg
PMSF ⁄mL] (Chargelegue et al., 2005) supplemented with 20%
(w ⁄ v) Dowex-1, a strong base anion-exchange resin that has
been shown to bind phenols and other small molecules (Gray,
1978). The homogenate was centrifuged at 10 000 g for
30 min and the supernatant retained. The pH of the superna-
tant was shifted to pH 5.0 with phosphoric acid, and precipi-
tated proteins were removed by centrifugation at 13 000 g for
5 min at room temperature. The pH of the supernatant was
adjusted to pH 7.0 with 10 M NaOH and aliquots loaded onto
strong anion-exchange Vivapure Q spin columns (Sartorius
Stedim, Epsom, Surrey, UK), retaining the flow-through. The
partially purified material was dialysed against 10 mM
(NH4)2CO3 using SnakeSkin 3500 MWCO dialysis tubing (Pierce
Biotechnology, Rockford, IL) at 4 C. The preparation was then
frozen in liquid nitrogen and lyophilized in an Edwards EF4 Mo-
dulyo Freeze-drier with the chamber at )60 C.
The p24 content of the preparation was determined by p24-
specific ELISA, using mouse anti-p24 antiserum and horseradish
peroxidase (HRP)-linked sheep anti-mouse IgG. Six serial twofold
dilutions of the preparation were loaded in triplicate, together
with E. coli p24 standards (AG6054; Aalto Bio Reagents, Rath-
farnham Village, Dublin, Ireland). The protein content of plant
extracts was determined using the bicinchoninic acid (BCA)
Protein Assay kit (Pierce Biotechnology) with bovine serum
albumen standards.
Analysis of nicotine content
The nicotine content of tobacco leaves and the p24-Nef prepa-
ration was determined by HPLC, following extraction into acidic
methanol (Silva et al., 1998). Triplicate samples (10 mg) of
freeze-dried leaves and the partially purified p24-Nef prepara-
tion were incubated with 1 mL of 40% methanol, 0.01% HCl
overnight at 20 C in the dark in an orbital shaker. The samples
were centrifuged at 12 000 g for 10 min, and the supernatant
passed through a 0.2-mm filter into an HPLC vial for analysis.
Samples (10 lL) were injected into the HPLC system (Accela;
Thermo Fisher Scientific, Waltham, MA) fitted with a Luna C18
column (100 · 2 mm, 3 lm particle size; Phenomenex, Tor-
rance, CA), previously equilibrated with Buffer A (2% ortho-
phosphoric acid, adjusted to pH 7.40 with triethylamine), and
eluted at a flow rate of 250 lL ⁄min with a mixture of 80%
(v ⁄ v) Buffer A and 20% (v ⁄ v) Buffer B (100% methanol). Nico-
tine was detected by its absorbance at 261 nm and eluted after
7–8 min. The amount of nicotine present was quantified by ref-
erence to standard amounts (39–2500 pmol) of nicotine
(N3876; Sigma-Aldrich, Poole, Dorset, UK) analysed on the
same column.
SDS–PAGE and immunoblotting
SDS–PAGE was performed according to Laemmli (1970) using
Mini Protean electrophoresis equipment (Bio-Rad, Hercules, CA).
Electrophoresis was carried out in 12% polyacrylamide gels,
which were either stained with Coomassie brilliant blue or sub-
jected to immunoblotting (Zhou et al., 2008). The membranes
were incubated with either mouse monoclonal antibody to p24
(9044; Abcam, Cambridge, UK) or anti-Nef sera (NIBSC, Potters
Bar, Hertfordshire, UK) diluted 1 : 1000, biotinylated sheep
anti-mouse IgG (GE Healthcare, Little Chalfont, Buckingham-
shire, UK) diluted 1 : 1000, streptavidin-biotinylated HRP com-
plex (GE Healthcare) diluted 1 : 1000, and detected using a
chemiluminescence reagent (PerkinElmer, Bar Hill, Cambridge,
UK) and Kodak X-Omat autoradiography film (Sigma-Aldrich).
Administration of plant-derived antigens to mice
Female C57BL ⁄ J and BALB ⁄C mice were obtained from Harlan
Laboratories (Bicester, Oxfordshire, UK) and kept in pathogen-
free conditions at St. George’s Hospital Medical School,
London, according to Institutional and Home Office guidelines.
Five-week-old C57BL ⁄ J mice were used for the experiment
using only subcutaneous injection, whereas 8-week-old
BALB ⁄C mice were used for experiments involving oral admin-
istration by gavage. Mice were injected subcutaneously at the
base of the tail with 100 lL of a PBS solution containing the
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appropriate amount of purified antigen and 10 lg of CTB
(C9903; Sigma-Aldrich) as an adjuvant. For oral immunization,
50 lg of the appropriate antigen (chloroplast-derived p24-Nef,
E. coli-derived p24 or E. coli-derived Nef), together with 10-lg
CTB as adjuvant, were administered by gavage using rounded-
tip feeding needles. The immunization studies of plant-derived
HIV antigens p24 and p24-Nef presented here were
conducted in compliance with National and Institutional
guidelines.
Collection and processing of blood samples
Mice were tail-bled at different times throughout the immuno-
logical analysis. Blood samples were incubated at 37 C for 1 h
to allow for clotting. Samples were then incubated at 4 C
overnight and centrifuged at 23 000 g at 4 C. The supernatant
was recovered and stored at )20 C. For culling, mice were an-
aesthetized by placing them in a chamber containing isoflurane
(Merial Animal Health, Harlow, Essex, UK), O2 and N2O. They
were culled by cardiac puncture (keeping the blood for further
processing and analysis) and subjected to neck and spinal chord
dislocation.
Collection and processing of faecal and vaginal
samples
Five fresh faecal pellets were collected from each individual
mouse 1 or 2 days before culling, and suspended in 4-lL PBS
with protease inhibitor cocktail (Roche, Burgess Hill, UK) per mg
of faecal pellet. The sample was incubated on ice for 1 h,
centrifuged twice at 27 000 g for 7 min and the supernatant
stored at )80 C before analysis. Vaginal washes were obtained
from individual anaesthetized mice by washing the vagina three
times with 30-lL volumes of PBS with protease inhibitor cock-
tail (Roche). The samples were incubated on ice for 30 min,
centrifuged at 30 000 g for 10 min and the supernatant stored
at )80 C before analysis. Faecal and vaginal samples were
analysed for p24- and Nef-specific IgA by ELISA, using biotin-
conjugated goat anti-mouse IgA (product 1040-08; Southern-
Biotech, Birmingham, AL) and streptavidin-horse radish peroxidase
(product DY998; R&D Systems, Minneapolis, MN).
ELISA of murine serum samples
Serum responses in mice were measured by antigen-specific
ELISA, as described by Obregon et al. (2006). Wells were coated
with chloroplast-derived p24, E. coli-derived p24 or E. coli-
derived Nef, and incubated in duplicate with twofold serial
dilutions of the serum samples. Bound p24- and Nef-specific anti-
bodies were detected with the following alkaline-phosphatase-
conjugated antibodies: for whole IgG responses, sheep anti-
mouse g-IgG (AP272; The Binding Site, Birmingham, UK); for
IgG1 responses, rabbit anti-mouse a-IgG1 (AP273; The Binding
Site); for IgG2a responses, rabbit anti-mouse a-IgG2a (MP003;
The Binding Site). Results from the immunoassays were expressed
as endpoint titres, defined as the reciprocal of the highest analyte
dilution that gave a reading above the cut-off (Frey et al., 1998).
The cut-off values were considered to be those of the back-
ground (pre-immunization sera) or negative control group.
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